The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Gradalis
Randomized double-blind placebo-controlled trial of primary maintenance vigil immunotherapy (VITAL study) in stage III/IV ovarian cancer: Efficacy assessment in BRCA1/2-wt patients.
 
Rodney Paul Rocconi
Speakers' Bureau - AstraZeneca; Clovis Oncology; Genentech
Expert Testimony - Johnson & Johnson
 
Elizabeth A. Grosen
No Relationships to Disclose
 
Sharad A. Ghamande
No Relationships to Disclose
 
John K. Chan
Honoraria - AstraZeneca; Clovis Oncology; Genentech/Roche; Tesaro
Consulting or Advisory Role - AstraZeneca; Biodesix; Clovis Oncology; Janssen Oncology; Mateon Therapeutics; Roche/Genentech; Tesaro
Speakers' Bureau - AstraZeneca; Clovis Oncology; Roche/Genentech; Tesaro
Research Funding - AstraZeneca (Inst); Roche/Genentech (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; Roche/Genentech; Tesaro
 
Minal A. Barve
No Relationships to Disclose
 
Jonathan Oh
No Relationships to Disclose
 
Devansu Tewari
No Relationships to Disclose
 
Peter C. Morris
No Relationships to Disclose
 
Erin E. Stevens
No Relationships to Disclose
 
Justin N. Bottsford-Miller
No Relationships to Disclose
 
Min Tang
Consulting or Advisory Role - Gradalis
 
Phylicia Aaron
Employment - Gradalis
 
Gladice Wallraven
Employment - Gradalis
Travel, Accommodations, Expenses - Gradalis
 
Ernest Bognar
Employment - Gradalis
Leadership - Gradalis
 
Luisa Manning
Employment - Gradalis
 
John J. Nemunaitis
Employment - Gradalis
Leadership - Gradalis
Stock and Other Ownership Interests - Gradalis
Honoraria - AstraZeneca
Consulting or Advisory Role - SymVivo
Speakers' Bureau - AstraZeneca
Patents, Royalties, Other Intellectual Property - Gradalis
Expert Testimony - Foundation Medicine
 
Brian M. Slomovitz
Consulting or Advisory Role - Agenus; AstraZeneca; Clovis Oncology; Genentech; Incyte; Tesaro
 
Thomas J Herzog
No Relationships to Disclose
 
Bradley J. Monk
Leadership - US Oncology
Honoraria - Abbvie; Advaxis; Agenus; Amgen; AstraZeneca; ChemoCare; ChemoID; Clovis Oncology; Conjupro Biotherapeutics; Eisai; Geistlich Pharma; Genmab; Immunogen; Immunomedics; Incyte; Janssen; Mateon Therapeutics; Merck; Myriad Pharmaceuticals; Nucana; OncoQuest; Perthera; Pfizer; Precision Oncology; Puma Biotechnology; Roche/Genentech; Samumed; Takeda; Tesaro; VBL Therapeutics
Consulting or Advisory Role - Abbvie; Advaxis; Amgen; AstraZeneca; Cerulean Pharma; ChemoCare; ChemoID; Clovis Oncology; Eisai; Geistlich Pharma; Immunogen; Incyte; Mateon Therapeutics; Merck; Myriad Pharmaceuticals; Nucana; OncoMed; OncoSec; Perthera; Pfizer; Precision Oncology; Roche/Genentech; Samumed; Takeda; Tesaro; VBL Therapeutics
Speakers' Bureau - AstraZeneca; Clovis Oncology; Janssen; Roche/Genentech; Tesaro
Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)
 
Robert L. Coleman
Consulting or Advisory Role - Abbvie; Abbvie/Stemcentrx; Agenus; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Genentech/Roche; Genmab; Immunogen; Novocure; Oncolytics; OncoMed; OncoSec; Sotio; Tesaro
Research Funding - Abbott/AbbVie; Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Johnson & Johnson; Merck; OncoMed; Roche/Genentech
Travel, Accommodations, Expenses - Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Clovis Oncology; GOG Foundation; Merck; Research to Practice; Roche/Genentech; Sotio; Vaniam Group